(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 41.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 38.38%.
Immunic's earnings in 2026 is -$97,172,000.On average, 10 Wall Street analysts forecast IMUX's earnings for 2026 to be -$39,596,074, with the lowest IMUX earnings forecast at -$85,663,204, and the highest IMUX earnings forecast at -$6,849,403. On average, 9 Wall Street analysts forecast IMUX's earnings for 2027 to be -$47,684,894, with the lowest IMUX earnings forecast at -$67,763,430, and the highest IMUX earnings forecast at -$12,328,926.
In 2028, IMUX is forecast to generate -$16,634,265 in earnings, with the lowest earnings forecast at -$65,206,320 and the highest earnings forecast at $73,973,556.